Valerion Therapeutics, LLC
Medford
About Valerion Therapeutics, LLC
Valerion Therapeutics, LLC (formerly 4s3 Bioscience) is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery. Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of the 4s3 delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $100K – $500K
- Total funding: $32.1M
- Funding stage: Early Stage Venture
- Last round: Product Crowdfunding (Dec 2024)
- Website: valerion.com
- Phone: 978-341-8183
Industries & Categories
Biotechnology, Genetics, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/valerion-therapeutics-llc-62226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.